$ News

Novo Nordisk: Consider The Counterfactual

Akero Therapeutics (AKRO): Examining Valuation After Strong Year-to-Date Share Price Gains

Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025

Assessing Akero Therapeutics (AKRO) Valuation After Strong Share Price Gains

Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going.

Akero Therapeutics (AKRO) Jumps 16% on $5.2-Billion Novo Nordisk Merger

Why Akero Therapeutics Stock Trounced the Market on Thursday

Novo Nordisk to Buy Akero Therapeutics in $5.2 Billion Deal

Market Chatter: Novo Nordisk CEO Poised to Take Risks in Weight-Loss Rivalry

Stocks Fall on Higher Bond Yields and Weakness in Chipmakers

Novo Nordisk's Akero Deal: Panic Buy Or Wise Decision? Here's My Take

Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $4.7 Billion Buyout

Novo joins MASH dealmaking surge with $4.7B Akero buyout

Akero Therapeutics Stock Soars. Novo Nordisk Is Buying the Biotech for Up to $5.2 Billion.

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion

Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion

Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio

AI-Driven MASH Data from Phase 2b Trials Might Change The Case For Investing In Akero Therapeutics (AKRO)

Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025

CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU